|
See related Cetrotide powd for inj[欣得泰 乾粉注射劑] information |
|
|
|
製造商 |
Merck Serono |
|
代理/經銷商 |
Merck Serono |
|
成份 |
Cetrorelix acetate |
|
適應症 |
Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick-up & assisted reproductive techniques. |
|
用量 |
By SC inj. 0.25 mg vial Administer once daily, at 24 hr intervals, in the morning or evening. Administration in the morning: commence on day 5 or 6 of ovarian stimulation (approx 96-120 hr after start of ovarian stimulation) with urinary or recombinant gonadotropins. Continue throughout the gonadotropin treatment period including the day of ovulation induction. Administration in the evening: commence on day 5 of ovarian stimulation (approx 96-108 hr after start of ovarian stimulation) with urinary or recombinant gonadotropins. Continue throughout the gonadotropin treatment period until the evening prior to the day of ovulation induction. 3 mg vial Administer on day 7 of ovarian stimulation (approx 132-144 hr after start of ovarian stimulation) with urinary or recombinant gonadotropins. If the follicle growth does not allow ovulation induction on the 5th day after inj of Cetrotide 3 mg, additionally administer Cetrotide 0.25 mg once daily beginning 96 hr after the inj of Cetrotide 3 mg until the day of ovulation induction. |
|
過量 |
View Cetrotide[欣得泰] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. |
|
禁忌 |
Hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol. Pregnancy & lactation. Postmenopausal women. Moderate & severe renal & hepatic impairment. |
|
注意事項 |
May give rise to ovarian hyperstimulation syndrome. Luteal phase support should be given where necessary. Cetrotide should be used in repeated ovarian stimulation only after careful risk/benefit eva luation. |
|
不良反應 |
Transient local redness, swelling & itch. Nausea, headache. Abdominal pain, tension, nausea, vomiting, diarrhea & breathing difficulties may indicate ovarian hyperstimulation syndrome.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
[Click for Cetrotide[欣得泰] detailed prescribing infomation]
View more drug interactions with Cetrotide[欣得泰] |
|
使用上注意 |
For caution against possible variation of physical aspect of medicine... click to view Cetrotide[欣得泰] detailed prescribing infomation |
|
儲存 |
View Cetrotide[欣得泰] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Cetrotide[欣得泰] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Cetrotide[欣得泰] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Cetrotide 乾粉注射劑 |
|
Cetrotide 0.25 mg x 7's |
|
Cetrotide 3 mg x 1's |
|
|
|
Manufacturer: |
Merck Serono |
|
Distributor: |
Merck Serono |
|
|
|
